ADAR1-dependent editing regulates human β cell transcriptome diversity during inflammation

Florian Szymczak, Roni Cohen-Fultheim, Sofia Thomaidou, Alexandra Coomans de Brachène, Angela Castela, Maikel Colli, Piero Marchetti, Erez Levanon, Decio Eizirik, Arnaud Zaldumbide

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Introduction: Enterovirus infection has long been suspected as a possible trigger for type 1 diabetes. Upon infection, viral double-stranded RNA (dsRNA) is recognized by membrane and cytosolic sensors that orchestrate type I interferon signaling and the recruitment of innate immune cells to the pancreatic islets. In this context, adenosine deaminase acting on RNA 1 (ADAR1) editing plays an important role in dampening the immune response by inducing adenosine mispairing, destabilizing the RNA duplexes and thus preventing excessive immune activation. Methods: Using high-throughput RNA sequencing data from human islets and EndoC-βH1 cells exposed to IFNα or IFNγ/IL1β, we evaluated the role of ADAR1 in human pancreatic β cells and determined the impact of the type 1 diabetes pathophysiological environment on ADAR1-dependent RNA editing. Results: We show that both IFNα and IFNγ/IL1β stimulation promote ADAR1 expression and increase the A-to-I RNA editing of Alu-Containing mRNAs in EndoC-βH1 cells as well as in primary human islets. Discussion: We demonstrate that ADAR1 overexpression inhibits type I interferon response signaling, while ADAR1 silencing potentiates IFNα effects. In addition, ADAR1 overexpression triggers the generation of alternatively spliced mRNAs, highlighting a novel role for ADAR1 as a regulator of the β cell transcriptome under inflammatory conditions.

Original languageEnglish
Article number1058345
JournalFrontiers in Endocrinology
Volume13
DOIs
StatePublished - 28 Nov 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022 Szymczak, Cohen-Fultheim, Thomaidou, de Brachène, Castela, Colli, Marchetti, Levanon, Eizirik and Zaldumbide.

Funding

This research has been supported by the Israel Science Foundation (grant numbers 2039/20 and, 231/21 to EL), the DON Foundation and the Dutch Diabetes Research Foundation, JDRF and by IMI2-JU under grant agreement No 115797 (INNODIA) and No 945268 (INNODIA HARVEST). These joint undertakings receive support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA), JDRF, and the Leona M. and Harry B. Helmsley Charitable Trust. DE acknowledges the support of grants from the Welbio-FNRS (Fonds National de la Recherche Scientifique) (WELBIO-CR-2019C-04), Belgium; the JDRF (3-SRA-2022-1201-S-B); the National Institutes of Health Human Islet Research Network Consortium on Beta Cell Death and Survival from Pancreatic β-Cell Gene Networks to Therapy [HIRN-CBDS]) (grant U01 DK127786). F.S. is supported by a Research Fellow (Aspirant) fellowship from the Fonds National de la Recherche Scientifique (FNRS, Belgium).

FundersFunder number
IMI2-JU945268, 115797
National Institutes of HealthU01 DK127786
Leona M. and Harry B. Helmsley Charitable Trust
Horizon 2020 Framework Programme
European Federation of Pharmaceutical Industries and Associations
Juvenile Diabetes Research Foundation Netherlands
Fonds De La Recherche Scientifique - FNRS3-SRA-2022-1201-S-B, WELBIO-CR-2019C-04
Diabetes Fonds
Israel Science Foundation2039/20, 231/21
Stichting Diabetes Onderzoek Nederland

    Keywords

    • RNA editing
    • T1D (type 1 diabetes)
    • beta cell (β cell)
    • inflammation
    • transcriptome

    Fingerprint

    Dive into the research topics of 'ADAR1-dependent editing regulates human β cell transcriptome diversity during inflammation'. Together they form a unique fingerprint.

    Cite this